ClinicalTrials.gg
RecruitingNCT04457154Updated Feb 25, 2025

Pediatric Post-Approval Registry

An observational study in Obstructive Sleep Apnea, sponsored by Inspire Medical Systems, Inc.. Recruiting at 8 sites in United States. Open to participants aged 18 Years to 21 Years. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Inspire Medical Systems, Inc. · Observational

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc. — 5 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · Inspire Medical Systems, Inc..

Started
2021
with 1 other
Observational
4 of 13
3 open now
Registered
7th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc., this one is one of 2 that started in 2021, is one of 4 observational ones, and was the 7th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

5 of the 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc. are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc., or all of them as a file.
02

Study summary

This registry is a prospective, multi-center, single-arm study of pediatric subjects (ages 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation (UAS) System for the treatment of moderate or severe obstructive sleep apnea (OSA). Implanted subjects will be followed for 5 years post-implant.

Read the detailed description

This registry is a prospective, multi-center, single-arm study of pediatric subjects (ages 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation (UAS) System for the treatment of moderate or severe obstructive sleep apnea (OSA). Implanted subjects will be followed for 5 years post-implant.

Subjects will be recruited in accordance with the approved Inspire UAS indication for use and will only include those subjects who are within the new age indication (18-21 years of age). Implanted subjects must meet the registry eligibility criteria. Those subjects that are enrolled but fail to meet the eligibility criteria will be considered screen failures.

This registry will collect safety and effectiveness data on 60 implanted subjects at a minimum of 5 qualified clinical centers in the United States.

Study data will be collected at the following timepoints:

Baseline (pre-implant) Implant Activation (1 month post-implant) 6 Months post-implant

1, 2, 3, 4, 5 years post-implant

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • Pediatric
  • Apnea-hypopnea Index
  • Sleep Breathing Disorders
04

Who can participate

Ages eligible
18 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric subjects (ages 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation (UAS) System for the treatment of moderate or severe obstructive sleep apnea (OSA).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is between 18 and 21 years of age;
  2. Subject has a diagnosis of moderate to severe OSA (15 ≤ AHI ≤ 65) based on a recent sleep study;
  3. Subject has documented failure of, or intolerance to, positive airway pressure treatments, despite attempts to improve compliance;
  4. Subject is for, or not effectively treated by, adenotonsillectomy;
  5. Subject has followed standard of care in considering all other alternative/adjunct therapies;
  6. Subject is willing and able to have stimulation hardware permanently implanted and to use the patient remote to activate the stimulation;
  7. Subject is willing and able to return for follow-up visits, undergo sleep studies (including in-lab and at-home), and complete questionnaires related to the registry;
  8. Subject is willing and able to provide .

Exclusion criteria

Exclusion Criteria:

  1. Subject has a combination of central + mixed apneas > 25% of the total apnea-hypopnea index (AHI);
  2. Subject has any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate;
  3. Subject has any condition or procedure that has compromised neurological control of the upper airway;
  4. Subject is unable, or does not have the necessary assistance, to operate the patient remote;
  5. Subject is pregnant or plans to become pregnant;
  6. Subject has an implantable device that may be susceptible to unintended interaction with the Inspire System;
  7. Subject has a terminal illness with \< 12 months;
  8. Any other reason the investigator deems the subject is unfit for participation in the registry.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Registry Population

    Pediatric subjects (age 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation System for the treatment of moderate to severe obstructive sleep apnea (OSA)

    Device: Inspire Upper Airway Stimulation System

Interventions

  • DeviceInspire Upper Airway Stimulation System

    Implant of the Inspire Upper Airway Stimulation System

06

What researchers measure

Primary outcomes

  1. Evaluation of device and/or procedure related adverse events over time

    relevant adverse events will be collected and reported

    Time frame: Implant through 5 years post-implant

  2. Evaluation of the improvement of Apnea Hypopnea Index (AHI) over time

    Baseline (pre-implant) AHI compared to AHI after implant (collected and reported at annual study visits). The Apnea Hypopnea Index (AHI) is the number of apnea and hypopnea events per hour of sleep. A lower AHI indicates less severe sleep apnea.

    Time frame: through 5 years post-implant

Secondary outcomes

  1. Evaluation of improvement in Oxygen Desaturation Index (ODI) over time

    Baseline (pre-implant) Oxygen Desaturation Index (ODI) compared to ODI after implant (collected and reported at annual study visits). The Oxygen Desaturation Index (ODI) is the number of oxygen desaturations, with at least a 4% drop from baseline, per hour. A lower ODI indicates less severe sleep apnea.

    Time frame: through 5 years post-implant

  2. Evaluation of improvement in T90 (defined as total sleep time spent with arterial oxygen saturation (SaO2) < 90%) over time

    Baseline (pre-implant) T90 compared to T90 after implant (collected and reported at annual study visits). T90 is defined as the total sleep time spent with arterial oxygen saturation (SaO2) \< 90%. A lower T90 indicates less severe sleep apnea.

    Time frame: through 5 years post-implant

  3. Evaluation of improvement of Epworth Sleepiness Scale (ESS) over time

    Baseline (pre-implant) Epworth Sleepiness Scale (ESS) compared to ESS after implant (collected and reported at annual study visits). The Epworth Sleepiness Scale is a validated, self-report instrument that rates a subject's tendency to fall asleep in eight common daily situations. Scores range from 0 to 24, with a lower score indicating less daytime sleepiness. An ESS score of 10 or less is equivalent to the normalized population.

    Time frame: through 5 years post-implant

07

Study locations

7 of 8 sites recruiting
  • Childrens Hospital of Colorado
    Aurora, Colorado 80045, United States
    Recruiting
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
    Terminated

    Not enrolling at this site.

  • Duke University
    Durham, North Carolina 27705, United States
    Recruiting
  • Cincinnati Childrens Hospital
    Cincinnati, Ohio 45229, United States
    Recruiting
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19406, United States
    Recruiting
  • Children's Hospital of Pittsburgh
    Sewickley, Pennsylvania 15143, United States
    Recruiting
  • University of Texas Southwestern/Children's Hospital of Dallas
    Dallas, Texas 75207, United States
    Recruiting
  • Children's Hospital of the King's Daughters/East Virginia Medical School
    Norfolk, Virginia 23507, United States
    Recruiting
    • Lakshya Enugu · Contactenugul@evms.edu
    • Cristina Baldassari, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2027, 73 months after the start.

Of 36 industry-sponsored observational studies under Sleep Apnea, Obstructive, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 93. This study's planned 73 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 7, 2020
StartActual
Nov 30, 2021
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04457154
Lead sponsor
Inspire Medical Systems, Inc.
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Nov 30, 2021
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Feb 25, 2025

Study contacts

Gwen Gimmestad
Contact
gwengimmestad@inspiresleep.com
763-392-9966
Mike Swierzewski, MS
Contact
michael.swierzewski@inspiresleep.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion